Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 2131 results found since Jan 2013.
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
CONCLUSIONS: Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.PMID:36670508 | DOI:10.1186/s13046-022-02578-w
Source: Clinical Genitourinary Cancer - January 20, 2023 Category: Cancer & Oncology Authors: Magdalena Keller Katharina Rohlf Annika Glotzbach Gregor Leonhardt Simon L üke Katharina Derksen Özlem Demirci Defne G öçener Mohammad AlWahsh J örg Lambert Cecilia Lindskog Marcus Schmidt Walburgis Brenner Matthias Baumann Eldar Zent Mia-Lisa Zischi Source Type: research
Development of hyaluronic acid-anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer
Drug Deliv Transl Res. 2023 Jan 15. doi: 10.1007/s13346-022-01288-2. Online ahead of print.ABSTRACTPlK1 has a significant role in the development of breast cancer. Thus, silencing of PlK1 gene may arrest the growth of breast cancer. However, the in vivo stability of PlK1 siRNA after injection remains a challenge to target the specific site. The delivery of siPlK1 RNA via viral vector and amine group-terminated dendrimer is associated with immune reaction and cellular cytotoxicity. Thus, in the present study, hyaluronic acid-functionalized and -thiolated polycaprolactone nanoparticles (SH-HPP NPs) were developed for enhanci...
Source: Cancer Control - January 14, 2023 Category: Cancer & Oncology Authors: Dolly Jain Awesh K Yadav Source Type: research
Caveolin-1-deficient fibroblasts promote migration, invasion, and stemness via activating the TGF- β/Smad signaling pathway in breast cancer cells
This study refreshingly points out that CAV-1 deficiency in fibroblasts enhances TGF-β1 secretion and then activates the TGF-β1/Smad signaling pathway of BCCs, thus promoting the metastasis and stemness of BCCs. Collectively, our findings indicate an unexpected role of CAV-1 deficiency in fibroblasts and the tumor microenvironment as a permissive factor, which is regulated by the TGF-β1 signaling pathway in BCCs.PMID:36604141 | DOI:10.3724/abbs.2022150
Source: Acta Biochimica et Biophysica Sinica - January 5, 2023 Category: Biochemistry Authors: Qingyun Huang Longyuan Wu Yi Wang Xinyu Kong Xinhua Xiao Qiyuan Huang Miao Li Yujia Zhai Fuxiu Shi Ruichen Zhao Junpei Zhong Lixia Xiong Source Type: research
Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC
This study demonstrates that the targeted co-delivery of drug and siRNA has a strong potential to overcome drug resistance in TNBC cells.PMID:36586658 | DOI:10.1016/j.ijbiomac.2022.12.266
Source: International Journal of Biological Macromolecules - December 31, 2022 Category: Biochemistry Authors: Pramod Kumar Rajesh Salve Kishore M Paknikar Virendra Gajbhiye Source Type: research
Significance of Oct-4 transcription factor as a pivotal therapeutic target for CD44 < sup > + < /sup > /24 < sup > - < /sup > mammary tumor initiating cells: Aiming at the root of the recurrence
In this study, we have attempted to identify previously unrecognized CSC survival factors that can be used as druggable targets for bCSCs apoptosis regulators isolated from the TNBC line, MDA MB 468. After a thorough literature review, Oct-4 was identified as the most promising marker for its unique abundance in cancer and absence in normal cells and the contribution of Oct-4 to the sustenance of cancer cells. We then validated a very high expression of Oct-4 in the MDA MB 468 bCSCs population using flow-cytometry. The loss of Oct-4 was carried out using small interfering RNA (siRNA)-mediated knockdown in the bCSCs, follow...
Source: Cell Biology International - December 27, 2022 Category: Cytology Authors: Utsav Sen Shanooja Shanavas Apoorva H Nagendra Muhammad Nihad Debajit Chaudhury Hari K Rachamalla Rajkumar Banerjee Sudheer Shenoy P Bipasha Bose Source Type: research
siRNA and targeted delivery systems in breast cancer therapy
Clin Transl Oncol. 2022 Dec 23. doi: 10.1007/s12094-022-03043-y. Online ahead of print.ABSTRACTRecently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer therapy appears inevitable. siRNA is a RNAi tool with capacity of suppressing target gene. Owing to overexpression of oncogenic factors in cancer, siRNA can be used for suppressing those pathways. This review emphasizes the function of siRNA in treatment of breast tumor. The anti-apoptotic-related genes including...
Source: Clinical Breast Cancer - December 23, 2022 Category: Cancer & Oncology Authors: Sepideh Mirzaei Mahshid Deldar Abad Paskeh Maliheh Entezari Seyed Hesamoddin Bidooki Vahideh Javadian Ghaleh Shamin Rezaei Elahe Sadat Hejazi Amirabbas Kakavand Mitra Behroozaghdam Abolfazl Movafagh Afshin Taheriazam Mehrdad Hashemi Saeed Samarghandian Source Type: research
